Members Login
ACTG Network
  • Home
  • About
    • About the ACTG
    • Leadership and Organizational Matrix
    • ACTG Committees and Centers
    • Underrepresented Populations
    • Contact the LOC
  • Clinical Trials
    • About the Clinical Trials Process
    • Active Clinical Trials
    • Clinical Trials Resources
    • Study Result Slides
  • Sites
  • Community
    • Global Community Advisory Board
    • Community Resources
    • They Became My Family
  • Publications
  • News
    • In Memorium
    • Press Releases & Announcements
    • Newsletters
  • For Researchers
    • Submit a Proposal
    • Small Clinical Trials RFA –HIV Remission & Cure
    • Specimen Repository Website
    • HIV Databases

Greensboro CRS

Location

Wendover Medical Center, 301 East Wendover Avenue, Suite 111
Greensboro, NC 27401
United States of America

www.conehealth-rcid.com

CRS Coordinator

Kim Epperson
kim.epperson@conehealth.com
336-832-3262

CRS Leader

Cornelius Van Dam
cornelius.vandam@conehealth.com
336-832-8560

Studies
  • A5128: US Genomic Sampling
  • A5321: Decay of HIV-1 Reservoirs in Participants on Long-Term Antiretroviral Therapy: The ACTG HIV Reservoirs Cohort (AHRC) Study
  • A5322: Long-Term Follow-up of Older HIV-infected Adults in the ACTG: Addressing Issues of Aging, HIV Infection and Inflammation (HAILO)
  • A5332: REPRIEVE Trial
  • A5354: Early ART in Acute HIV
  • A5357: A Study of Long-Acting Cabotegravir Plus VRC01LS to Maintain Viral Suppression in HIV-1-Infected Adults
  • A5359: The LATITUDE Study
  • A5361s: Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
  • A5366: Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation with Histone Deacetylase Inhibitors
  • A5368:Anti-PD-1 Antibody in HBV Infected on Suppressive Antiviral Therapy
  • A5380: Glecaprevir/pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection (PURGE-C)
  • A5379: B-Enhancement of HBV vaccination in persons living with HIV (BEe-HIVe): Evaluation of HEPLISAV-B
  • A5391: Doravirine for Persons with Excessive Weight Gain on Integrase Inhibitors and Tenofovir Alafenamide (The Do IT Study)

Mission

The mission of the ACTG Network
is to cure HIV and reduce the
burden of disease due to HIV
and its complications, including
tuberculosis and viral hepatitis.

Useful Links

Government Resources
Clinical Trials Resources
Grants and Contracts
New Members

© ACTG. All Rights Reserved. | admin login